[1] Nicolson GL, Blaustein J, Etzler ME.Characterization of two plant lectins from Ricinus communis and their quantitative interaction with a murine lymphoma[J].Biochemistry, 1974, 13(1):196-204. [2] 庄书斐, 叶其壮.肿瘤血管生成的分子机制及其治疗前景[J].中国药理学通报, 2000, 16(2):128-132. [3] 林, 李承博, 侯东泽.肿瘤生物治疗新进展[J].中国实用医药, 2009, 4(1):225-226. [4] Sandvig K, van Deurs B.Transport of protein toxins into cells:pathways used by ricin, cholera toxin and Shiga toxin[J].FEBS Lett, 2002, 529(1):49-53. [5] Zhen Y.Advances in research on monoclonal antibody agents for cancer therapy[J].Zhongguo Yi Xue Ke Xue Yuan Xue Bao, 2000, 22(1):9-13. [6] Gullick WJ.Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers[J].Br Med Bull, 1991, 47(1):87-98. [7] 李哲, 袁守军.表皮生长因子受体酪氨酸激酶抑制剂在肿瘤治疗中的应用[J].中国临床药理学与治疗学, 2004, 9(4):361-364. [8] Davies DE, Chamberlin SG.Targeting the epidermal growth factor receptor for therapy of carcinomas[J].Biochem Pharmacol, 1996, 51(9):1101-1110. [9] Carlsson J, Drevin H, Axé n R.Protein thiolation and reversible protein-protein conjugation.N-Succinimidyl 3-(2-pyridyldithio) propionate, a new heterobifunctional reagent[J].Biochem J, 1978, 173(3):723-737. [10] Carter PJ, Senter PD.Antibody-drug conjugates for cancer therapy[J].Cancer J, 2008, 14(3):154-169. |